Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2361]

NCI’s precision medicine initiatives

Dr Shakun Malik - National Cancer Institute, USA

NCI’s precision medicine initiatives ( Dr Shakun Malik - National Cancer Institute, USA )

Immunotherapy in SCLC

Prof Dean Fennell - University of Leicester, Leicester, UK

Immunotherapy in SCLC ( Prof Dean Fennell - University of Leicester, Leicester, UK )

Immunotherapy in NSCLC

Prof Giuseppe Giaccone - Georgetown University, Washington DC, USA

Immunotherapy in NSCLC ( Prof Giuseppe Giaccone - Georgetown University, Washington DC, USA )

Omics, early detection and novel therapies: Epigenetic studies

Dr Adele Murrell - University of Bath, Bath, UK

Omics, early detection and novel therapies: Epigenetic studies ( Dr Adele Murrell - University of Bath, Bath, UK )

We should use PDL1 and other biomarkers for selecting patients for immune...

Dr Mary O’Brien - The Royal Marsden NHS Foundation Trust, London, UK

We should use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies ( Dr Mary O’Brien - The Royal Marsden NHS Foundation Trust, London, UK )

We should not use PDL1 and other biomarkers for selecting patients for immune...

Prof Gordon McVie - King's College London, London, UK

We should not use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies ( Prof Gordon McVie - King's College London, London, UK )

Using PDL1 and other biomarkers in patient selection for immunology: Q & A

Dr O'Brien and Prof McVie

Using PDL1 and other biomarkers in patient selection for immunology: Q & A ( Dr O'Brien and Prof McVie )

How do cancer registries operate in the UK?

Dr Jem Rashbass - Public Health England, UK

How do cancer registries operate in the UK? ( Dr Jem Rashbass - Public Health England, UK )

Hope, hype, misinformation and clinical evidence

Prof Michael Brada - University of Liverpool, Liverpool, UK

Hope, hype, misinformation and clinical evidence ( Prof Michael Brada - University of Liverpool, Liverpool, UK )

A model-based selection approach to identify suitable indications for proton...

Prof Johannes Langendijk - University of Groningen, Groningen, Netherlands

A model-based selection approach to identify suitable indications for proton therapy ( Prof Johannes Langendijk - University of Groningen, Groningen, Netherlands )

IBCD 2016: Patient access and regulatory challenges

Dr Denis Lacombe - EORTC Director General

IBCD 2016: Patient access and regulatory challenges ( Dr Denis Lacombe - EORTC Director General )

Taking complex genomic analysis into practice

Dr Philip Beer - Sanger Institute, Hinxton, UK

Taking complex genomic analysis into practice ( Dr Philip Beer - Sanger Institute, Hinxton, UK )

More from ecancer